Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
University of Michigan Rogel Cancer Center
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
Affiliated Hospital of Nantong University
Brown University
Eli Lilly and Company
ImmunityBio, Inc.
University of Pennsylvania
TORL Biotherapeutics, LLC
Nantes University Hospital
The Second Affiliated Hospital of Fujian Medical University
Tongji Hospital
Ruijin Hospital
Medical College of Wisconsin
Affiliated Hospital of Jiangsu University
University Hospital, Basel, Switzerland
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Institute of Hematology & Blood Diseases Hospital, China
Case Comprehensive Cancer Center
Beijing GoBroad Hospital
First Affiliated Hospital Xi'an Jiaotong University
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Nationwide Children's Hospital
Institute of Hematology & Blood Diseases Hospital, China
University of Pennsylvania
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Second Affiliated Hospital, School of Medicine, Zhejiang University
Peking University Cancer Hospital & Institute
Zhengzhou University